雷爾馬達治療公司
US ˙ NasdaqCM ˙ US75955J4022

SecurityRLMD / Relmada Therapeutics, Inc.
InstitutionInvesco Ltd.
Latest Disclosed Ownership22,442 shares
Latest Disclosed Value $ 156,196
Invesco Ltd. ownership in RLMD / Relmada Therapeutics, Inc.

On May 12, 2026 - Invesco Ltd. filed a 13F-HR form disclosing ownership of 22,442 shares of Relmada Therapeutics, Inc. (US:RLMD) valued at $156,196 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2023 disclosing 0 shares of Relmada Therapeutics, Inc.. The current value of the position is $141,609 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F RELMADA THERAPEUTICS COM 75955J402 22,442 22,442 156 0.0000
2023-02-13 2022-12-31 13F RELMADA THERAPEUTICS COM 75955J402 0 -114,245 -100.00 0 -100.00
2022-11-14 2022-09-30 13F RELMADA THERAPEUTICS COM 75955J402 114,245 103,578 971.01 4,229 1,983.25 0.0014
2022-08-15 2022-06-30 13F RELMADA THERAPEUTICS COM 75955J402 10,667 1,545 16.94 203 -17.81 0.0001
2022-05-16 2022-03-31 13F RELMADA THERAPEUTICS COM 75955J402 9,122 9,122 247 0.0001
2021-05-17 2021-03-31 13F RELMADA THERAPEUTICS COM 75955J402 0 -267,155 -100.00 0 -100.00
2021-02-16 2020-12-31 13F RELMADA THERAPEUTICS COM 75955J402 267,155 2,190 0.83 8,568 -14.04 0.0025
2020-11-16 2020-09-30 13F RELMADA THERAPEUTICS COM 75955J402 264,965 -57,776 -17.90 9,968 -30.98 0.0034
2020-08-14 2020-06-30 13F RELMADA THERAPEUTICS COM 75955J402 322,741 56,623 21.28 14,443 59.12 0.0052
2020-05-15 2020-03-31 13F RELMADA THERAPEUTICS COM 75955J402 266,118 -3,119 -1.16 9,077 -13.55 0.0038
2020-02-14 2019-12-31 13F RELMADA THERAPEUTICS COM 75955J402 269,237 269,237 10,500 0.0033
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.